CLSI and APHL Announce New Teleconference Series
Alloantibody by Flow Cytometry and Solid Phase Assays (I/LA29-P)
New Antimicrobial Susceptibility Testing Standard (M100-S18)

CLSI and APHL Announce New Teleconference Series
Optimize the Use of CLSI Documents in Clinical and Public Health Laboratories
Wayne, Pennsylvania, USA—January 2008— The Clinical and Laboratory Standards Institute (CLSI) and the Association of Public Health Laboratories (APHL) have announced a joint venture to present educational programs to clinical and public health laboratories. Programs will be based on current CLSI documents and the intent is to help pathologists, managers, supervisors, and technologists learn how to optimize use of these documents in their laboratory.
Read full press release.

New CLSI Guideline Provides Optimal Methods for Utilizing Flow Cytometry and Solid Phase Assays
Wayne, Pennsylvania, USA—January 2008—The current and emerging technologies for detecting and characterizing human leukocyte antigen (HLA) alloantibodies provide powerful tools for predicting the risk of immunological response to a transplant. By standardizing methods, quality control, and clinical interpretations, transplant centers can more readily identify optimal donor-recipient pairs and encourage organ sharing.

Clinical and Laboratory Standards Institute (CLSI) has recently published a new document, Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Proposed Guideline (I/LA29-P), which describes criteria for optimizing flow cytometry crossmatching and the detection of HLA alloantibody by solid-phase methods in conventional and multiplex platforms.
Read full press release.

CLSI Publishes New Antimicrobial Susceptibility Testing Standard
Wayne, Pennsylvania, USA—January 2008— CLSI has recently published the annual update of the well-known antimicrobial susceptibility testing standard, Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement (M100-S18), which provides updates of the latest recommendations for detecting emerging resistance of aerobic bacteria—arranged in tabular format. The “breakpoints” included in the supplement are defined as specific values on the basis of which bacteria can be assigned to the clinical categories of susceptible, intermediate, or resistant. This essential information assists clinicians with drug selection, interpretation, and quality control using the procedures standardized in CLSI documents Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Ninth Edition (M2-A9); and Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Seventh Edition (M7-A7).
Read full press release. [ return to top ]